Centrum recommended hold rating on Abbott India with a target price of Rs 4480 in its research report dated November 28, 2016.
Centrum's research report on Abbott India
We expect AIL to perform well due to its strong brands, new product launches and entry into the high-margin vaccines segment. Key risks to our assumptions are slowdown in the domestic market and key upside risk would be faster growth of its brands. We recommend a switch to Sanofi India or Aurobindo Pharma.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.